These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16806797)

  • 1. Increases in circulating VEGF levels during COX-2 inhibitor treatment in breast cancer patients.
    Ueno T; Chow LW; Toi M
    Biomed Pharmacother; 2006 Jul; 60(6):277-9. PubMed ID: 16806797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
    Holmes CE; Huang JC; Pace TR; Howard AB; Muss HB
    Clin Cancer Res; 2008 May; 14(10):3070-6. PubMed ID: 18483373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes.
    Kümmel S; Eggemann H; Lüftner D; Thomas A; Jeschke S; Zerfel N; Heilmann V; Emons G; Zeiser T; Ulm K; Kobl M; Korlach S; Schmid P; Sehouli J; Elling D; Blohmer JU
    Anticancer Res; 2006; 26(2C):1719-26. PubMed ID: 16617567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant therapy with celecoxib to women with early stage breast cancer.
    Tfayli A; Yang J; Kojouri K; Kesserwan C; Jafari M; Ozer H
    Neoplasma; 2008; 55(2):122-6. PubMed ID: 18237249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
    Kang KB; Wang TT; Woon CT; Cheah ES; Moore XL; Zhu C; Wong MC
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):888-96. PubMed ID: 17293239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
    Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
    Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism].
    Kang HF; Wang XJ; Liu XX; Dai ZJ; Xue FJ; Xue XH
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Nov; 26(11):1599-602. PubMed ID: 17121709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
    Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
    Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy.
    Boidot R; Vegran F; Lizard-Nacol S
    Int J Mol Med; 2009 Feb; 23(2):285-91. PubMed ID: 19148555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celecoxib inhibits meningioma tumor growth in a mouse xenograft model.
    Ragel BT; Jensen RL; Gillespie DL; Prescott SM; Couldwell WT
    Cancer; 2007 Feb; 109(3):588-97. PubMed ID: 17177201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Change and clinic significance of serum VEGF level before and after breast cancer patients treated].
    Jing J; Zhao YB; Li HJ; Lü Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov; 37(6):889-92. PubMed ID: 17236587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells.
    Basu GD; Liang WS; Stephan DA; Wegener LT; Conley CR; Pockaj BA; Mukherjee P
    Breast Cancer Res; 2006; 8(6):R69. PubMed ID: 17156488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
    Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
    Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients.
    Chow LW; Loo WT; Wai CC; Lui EL; Zhu L; Toi M
    Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S298-301. PubMed ID: 16507397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer.
    Lowery AJ; Sweeney KJ; Molloy AP; Hennessy E; Curran C; Kerin MJ
    BMC Cancer; 2008 Sep; 8():279. PubMed ID: 18826631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer.
    Iovino F; Ferraraccio F; Orditura M; Antoniol G; Morgillo F; Cascone T; Diadema MR; Aurilio G; Santabarbara G; Ruggiero R; Belli C; Irlandese E; Fasano M; Ciardiello F; Procaccini E; Lo Schiavo F; Catalano G; De Vita F
    Cancer Invest; 2008; 26(3):250-5. PubMed ID: 18317965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum vascular endothelial growth factor in breast cancer.
    Byrne GJ; McDowell G; Agarawal R; Sinha G; Kumar S; Bundred NJ
    Anticancer Res; 2007; 27(5B):3481-7. PubMed ID: 17972505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.
    Végran F; Boidot R; Oudin C; Riedinger JM; Bonnetain F; Lizard-Nacol S
    Clin Cancer Res; 2006 Oct; 12(19):5794-800. PubMed ID: 17020986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.